The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
Open Access
- 26 July 2016
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 22 (2_suppl) , 47-59
Abstract
Background: Although there is still no cure for multiple sclerosis (MS), the introduction of several innovative drugs with modes of action different from that of the existing drug arsenal and the progress in monitoring disease progression by imaging and using biomarkers are currently causing a knowledge surge. This provides opportunities for improving patient disease management. New therapies are also under development and pose challenges to the regulatory bodies regarding the optimal design of clinical trials with more patient-focused clinical endpoints. Moreover, with the upcoming patent expiry of some of the key first-line MS treatments in Europe, regulatory bodies will also face the challenge of recommending marketing authorisation for generic and abridged versions based on appropriate requirements for demonstrating equality/similarity to the innovator’s product. Objective: The goal of this article is to improve the understanding of the relevant guidance documents of the European Medicines Agency (EMA) on clinical investigation of medicinal products and to highlight the issues that the agency will need to clarify regarding follow-on products of first-line MS treatments. Conclusion: Today, it is clear that close collaboration between patients, healthcare professionals, regulatory bodies and industry is crucial for developing new safe and effective drugs, which satisfy the needs of MS patients.Keywords
This publication has 35 references indexed in Scilit:
- Addressing the regulatory and scientific challenges in multiple sclerosis – a statement from the EU regulatorsMultiple Sclerosis Journal, 2014
- Gray matter damage predicts the accumulation of disability 13 years later in MSNeurology, 2013
- Multiple sclerosis: Prospects and promiseAnnals of Neurology, 2013
- Health‐related quality of life as an independent predictor of long‐term disability for patients with relapsing–remitting multiple sclerosisEuropean Journal of Neurology, 2013
- Disability outcome measures in multiple sclerosis clinical trials: current status and future prospectsThe Lancet Neurology, 2012
- Correlation of self-assessed fatigue and alertness in multiple sclerosisMultiple Sclerosis Journal, 2010
- Imaging biomarkers in multiple sclerosisJournal of Magnetic Resonance Imaging, 2010
- Ethics of placebo-controlled clinical trials in multiple sclerosisNeurology, 2008
- Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosisBrain, 2006
- Costs and quality of life of patients with multiple sclerosis in EuropeJournal of Neurology, Neurosurgery & Psychiatry, 2006